Ipca Laboratories Ltd

AI
Ipca Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Ipca Laboratories Ltd

₹ 1,938 -1.09%
11 Nov - close price
ipca.com BSE: 524494 NSE: IPCALAB
About

Ipca Laboratories is an integrated pharmaceutical company manufacturing branded and generic formulations, APIs and intermediates. Indian branded formulations are its core profit engine, complemented by formulation exports across Europe, Africa, the Americas, Asia, CIS and Australasia. The consolidated business includes Unichem Laboratories and its US, Brazil, Europe and South Africa operations.[1]

Key Points

Integrated nature of operations
Ipca Laboratories is a fully integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]

Business segments FY26:
API Business[3]
Ipca produces over 80 APIs; nearly 79% of the APIs and Intermediates business is from exports, making them one of India’s top exporters of APIs, serving over 100 countries around the globe.

Website BSE NSE
  • Market Cap ₹ 49,172 Cr.
  • Current Price ₹ 1,938
  • High / Low ₹ 2,039 / 1,294
  • Stock P/E 34.1
  • Book Value ₹ 342
  • Dividend Yield 0.31 %
  • ROCE 17.0 %
  • ROE 15.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 5.68 times its book value
  • Company has a low return on equity of 12.9% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma BSE 150 MidCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
2,034 2,053 2,033 2,093 2,355 2,245 2,247 2,309 2,556 2,392 2,388 2,788 2,910
1,673 1,722 1,711 1,700 1,913 1,782 1,818 1,892 2,012 1,859 1,905 2,119 2,236
Operating Profit 361 331 322 393 441 463 429 416 545 533 484 670 673
OPM % 18% 16% 16% 19% 19% 21% 19% 18% 21% 22% 20% 24% 23%
-1 91 -118 21 26 20 -179 33 -30 38 48 25 1
Interest 44 33 29 24 23 17 22 19 20 18 20 12 13
Depreciation 90 100 98 99 100 98 100 100 103 108 107 111 115
Profit before tax 225 289 77 290 345 368 128 331 392 446 404 572 547
Tax % 39% 23% 96% 31% 29% 25% 49% 29% 28% 18% 24% 26% 28%
136 221 1 199 246 276 64 233 281 364 307 424 389
EPS in Rs 5.72 7.09 2.35 7.58 9.05 9.78 2.67 9.19 11.14 12.86 11.79 15.84 14.79
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
3,144 2,867 3,156 3,258 3,746 4,619 5,395 5,797 6,204 7,662 8,897 9,599 10,479
2,604 2,573 2,705 2,803 3,051 3,715 3,843 4,472 5,272 6,338 7,166 7,609 8,119
Operating Profit 541 294 451 455 695 904 1,552 1,325 932 1,324 1,731 1,990 2,360
OPM % 17% 10% 14% 14% 19% 20% 29% 23% 15% 17% 19% 21% 23%
32 21 11 41 56 65 59 54 123 17 -114 80 112
Interest 32 35 27 28 22 20 12 11 48 141 88 79 62
Depreciation 180 163 173 178 182 210 209 232 262 357 398 418 440
Profit before tax 361 117 262 291 546 739 1,389 1,136 745 843 1,131 1,573 1,970
Tax % 28% 18% 26% 18% 19% 18% 17% 20% 34% 37% 30% 24%
254 93 195 239 442 604 1,141 890 479 523 785 1,184 1,484
EPS in Rs 10.07 3.69 7.71 9.49 17.60 23.99 44.94 34.85 18.58 21.57 29.08 44.98 55.28
Dividend Payout % 5% 0% 6% 5% 9% 10% 9% 11% 22% 19% 14% 0%
Compounded Sales Growth
10 Years: 13%
5 Years: 12%
3 Years: 16%
TTM: 12%
Compounded Profit Growth
10 Years: 30%
5 Years: 1%
3 Years: 37%
TTM: 46%
Stock Price CAGR
10 Years: 21%
5 Years: 12%
3 Years: 23%
1 Year: 47%
Return on Equity
10 Years: 14%
5 Years: 13%
3 Years: 13%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 25 25 25 25 25 25 25 25 25 25 25 25 25
Reserves 2,183 2,234 2,430 2,663 3,097 3,602 4,676 5,467 5,817 6,307 6,923 8,038 8,653
935 867 716 628 465 501 265 807 1,481 1,438 1,363 809 753
669 765 788 799 961 1,130 1,099 1,338 1,300 3,326 3,432 3,477 3,702
Total Liabilities 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 8,623 11,097 11,744 12,350 13,133
1,800 2,014 1,983 1,953 1,940 2,059 2,072 2,418 2,751 4,554 4,267 4,627 4,740
CWIP 267 129 95 73 66 133 235 306 140 343 622 773 832
Investments 16 26 136 87 120 310 505 989 626 862 980 844 1,055
1,729 1,723 1,746 2,003 2,422 2,756 3,254 3,924 5,105 5,339 5,875 6,106 6,507
Total Assets 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 8,623 11,097 11,744 12,350 13,133

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
468 709 282 341 501 570 1,090 856 806 945 1,321 1,142
-689 -218 -149 -135 -165 -509 -521 -851 -725 -1,215 -870 -247
251 -462 -159 -130 -183 -137 -306 427 507 -553 -283 -754
Net Cash Flow 29 29 -26 75 153 -76 264 432 588 -823 169 142
Free Cash Flow -207 463 147 206 322 277 731 380 347 543 551 486
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 100% 251% 74% 88% 88% 80% 86% 80% 110% 94% 97% 78%

Ratios

Consolidated / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 41 57 58 67 66 71 55 57 58 80 77 77
Inventory Days 293 289 290 286 316 294 337 337 276 350 336 353
Days Payable 97 145 130 137 154 135 140 101 83 110 111 122
Cash Conversion Cycle 237 200 218 216 228 229 251 293 251 321 302 308
Working Capital Days 68 61 74 80 88 88 103 102 71 111 101 109
ROCE % 14% 5% 9% 10% 16% 19% 31% 20% 11% 13% 15% 17%

Insights

In beta
Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Number of marketing divisions (domestic formulations)
count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
R&D expenditure as % of total income (standalone)
% ・Standalone data
Total permanent employees
count
Total number of manufacturing facilities
count
Number of countries exported to
count
Number of brands in domestic formulations
count ・Standalone data
Field force (Medical Representatives)
count ・Standalone data
Domestic formulation market share (IQVIA MAT)
% ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
46.29% 46.30% 46.30% 46.30% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72%
10.27% 10.51% 10.85% 10.83% 11.06% 10.75% 10.67% 10.42% 10.62% 10.63% 10.72% 11.53%
34.19% 34.05% 33.46% 33.90% 35.36% 35.73% 35.88% 36.45% 36.99% 37.13% 37.04% 36.60%
0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.00%
8.93% 8.82% 9.07% 8.64% 8.53% 8.45% 8.41% 8.09% 7.33% 7.21% 7.19% 7.15%
No. of Shareholders 82,80981,16584,75382,97590,18988,30685,58282,87077,67382,18482,06090,514

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls